drugset / Trial / NCT05027581
Chondrochymal® for Subjects With Knee Osteoarthritis (Knee OA)
Phase 2
Completed
72 enrolled
Taiwan Bio Therapeutics Inc.
A2 Healthcare Taiwan Corporation · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
This is a randomized, single-blind, parallel, active-controlled study to evaluate the efficacy and safety of bone marrow mesenchymal stem cells (BM-MSCs), Chondrochymal®, in subjects aged 40 to 80 with knee OA.
Timeline
- Start
- 2021-10-13
- Primary completion
- 2023-12-10
- Completion
- 2025-06-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bone marrow mesenchymal stem cells | Cell therapy | 5e+07 cells | Other |
| Comparator | Hyaluronic Acid | Other / unclassified | 60 mg | Other |